Polyunsaturated fatty acids supplementation impairs anti‐oxidant high‐density lipoprotein function in heart failure

Wurm, Raphael; Schrutka, Lore; Hammer, Alexandra; Moertl, Deddo; Berger, Rudolf; Pávó, Noémi; Lang, Irene; Goliasch, Georg; Huelsmann, M; Distelmaier, Klaus

doi:10.1111/eci.12998

Cited by 10 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Sherrat et al ( 59 ), when assessing HDL particle oxidation upon induction by copper and in the absence of LDL, observed greater power of EPA, relative to DHA, in delaying the onset of oxidation ( 59 ). In humans, Wurm et al ( 60 ) showed that after 12 weeks, the antioxidant function of HDL, as measured by the HDL inflammatory index, was significantly impaired in the group supplemented with ω-3 in a dose-dependent manner ( 60 ).…”

Section: Discussionmentioning

confidence: 99%

Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial

et al. 2022

View full text Add to dashboard Cite

Omega-3 (ω-3) fatty acids have been extensively studied for primary and secondary prevention of cardiovascular health, but their ability to modulate HDL functionality remains unclear. The purpose of this study was to investigate the role of ω-3, rich in eicosapentaenoic (EPA) and docosahexaenoic (DHA), on HDL functionality. For that, 147 individuals with high cardiovascular risk were randomized in ω-3 (1 g of fish oil each - 370 mg of EPA and 230 mg of DHA, 3 times per day total EPA+DHA = 1,800 mg) or ω-6 groups (1 g of sunflower oil each - 760 mg of linoleic acid, 3 times per day; total linoleic acid = 2,280 mg). Fasting blood samples were collected at baseline time and after 8 weeks of follow-up and, and the lipid profile and glucose metabolism were evaluated from plasma. From HDL, the fatty acid profile, apolipoproteins (Apo AI, CII and CIII), paraoxonase-1 (PON1), cholesteryl ester transfer protein (CETP), subfractions and antioxidant activity were investigated. Omega-3 improved large HDL (HDL = 28.7%) and reduced small HDL (HDL10 = −10.6%) and the non-esterified fatty acids in HDL (NEFAs-HDL) level (−16.2%). A significant reduction in CETP activity was observed in the ω-3group (Δ ω-6 = 3.60 pmol/ul/h and Δ ω-3 = −1.99 pmol/ul/h; p = 0.044). The antioxidant capacity estimated by Lag time analysis did not change after the ω-3intervention. Changes in PON1 and Apo AI were inversely associated with increased incorporation of EPA (AOR = 0.446; IC = 0.200–0.994) and DHA (AOR = 0.351; IC = 0.150–0.821) in HDL, respectively. Cardioprotective profile obtained by pooled fatty acids analysis was related to a decrease in Apo CIII (r = −0.638; p = 0.002) and CETP (r = −0.341; p = 0.012) and an increase in Apo CII (r = 0.448; p = 0.042) and PON1 (r = 0.388; p = 0.003). In conclusion, omega-3 was effective in the reduction of cardiovascular risk associated with HDL functionality by size improvement and changes in its lipid, antioxidant and enzyme composition.

show abstract

Section: Discussionmentioning

confidence: 99%

Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, in a small, double-blind, placebo-controlled, randomized study, the effect of n-3 PUFA supplementation on the high-density lipoprotein (HDL) antioxidant capacity was investigated. This study arose from the knowledge of the oxidative stress involvement in HF pathogenesis [ 77 ]. In fact, the association between the HDL antioxidant properties, HF, and clinical outcome was demonstrated.…”

Section: Heart Failure and Pufasmentioning

confidence: 99%

“…In fact, the association between the HDL antioxidant properties, HF, and clinical outcome was demonstrated. In addition, in some studies, an increase in HDL levels has been reported in HF patients following integration with n-3 PUFAs, with a consequent reduction in the risk of cardiovascular events (CVD) [ 77 ]. In this study, 40 subjects with advanced HF of non-ischemic origin, New York Heart Association (NYHA) class III or IV, who had been on therapy for three months or more were treated with 1 or 4 g of n-3 PUFAs per day for 12 weeks.…”

Section: Heart Failure and Pufasmentioning

confidence: 99%

“…It should be noted that in this study, only patients with non-ischemic HF of NYHA classes III or IV were treated, so it should be investigated as to whether the same results would also be obtained with other HF populations. Therefore, the contrasting effect of n-3 PUFA supplementation on the antioxidant capacity of HDLs could be related to the severity of the inflammatory condition [ 77 ]. In addition, recently, a study was conducted in which cardiac hypertrophy was generated by ligating the aortic arch, resulting in pressure overload in C58BL/6J mice.…”

Section: Heart Failure and Pufasmentioning

confidence: 99%

See 1 more Smart Citation

PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling

et al. 2021

View full text Add to dashboard Cite

Heart failure (HF) characterized by cardiac remodeling is a condition in which inflammation and fibrosis play a key role. Dietary supplementation with n-3 polyunsaturated fatty acids (PUFAs) seems to produce good results. In fact, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have anti-inflammatory and antioxidant properties and different cardioprotective mechanisms. In particular, following their interaction with the nuclear factor erythropoietin 2 related factor 2 (NRF2), the free fatty acid receptor 4 (Ffar4) receptor, or the G-protein coupled receptor 120 (GPR120) fibroblast receptors, they inhibit cardiac fibrosis and protect the heart from HF onset. Furthermore, n-3 PUFAs increase the left ventricular ejection fraction (LVEF), reduce global longitudinal deformation, E/e ratio (early ventricular filling and early mitral annulus velocity), soluble interleukin-1 receptor-like 1 (sST2) and high-sensitive C Reactive protein (hsCRP) levels, and increase flow-mediated dilation. Moreover, lower levels of brain natriuretic peptide (BNP) and serum norepinephrine (sNE) are reported and have a positive effect on cardiac hemodynamics. In addition, they reduce cardiac remodeling and inflammation by protecting patients from HF onset after myocardial infarction (MI). The positive effects of PUFA supplementation are associated with treatment duration and a daily dosage of 1–2 g. Therefore, both the European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association (ACC/AHA) define dietary supplementation with n-3 PUFAs as an effective therapy for reducing the risk of hospitalization and death in HF patients. In this review, we seek to highlight the most recent studies related to the effect of PUFA supplementation in HF. For that purpose, a PubMed literature survey was conducted with a focus on various in vitro and in vivo studies and clinical trials from 2015 to 2021.

show abstract

“…[39] A study by Wurm et al reported controversial results by showing that n3-PUFA supplementation diminishes the anti-oxidant function of HDL in nonischemic HF patients. [44] These divisive results demand further extensive studies and information in this regard.…”

Section: Inflammatory Factors and Plasma Lipidsmentioning

confidence: 99%

Omega-3 supplementation and outcomes of heart failure: A systematic review of clinical trials

Nomali,

Heidari,

Ayati

et al. 2024

Medicine

View full text Add to dashboard Cite

Backgrounds: Omega-3 supplements are endorsed for heart failure (HF) patients to reduce hospitalizations and mortality, offering anti-inflammatory and cardioprotective benefits. Methods: A comprehensive search was conducted in various databases until November 2022. Eligible studies included clinical trials on patients with HF. Data extraction covered study details, omega-3 specifics, outcomes, and limitations. The JADAD scale was used to assess the risk of bias in randomized controlled trials. Results: The review process involved 572 records from database searches, resulting in 19 studies after eliminating duplicates and screening. These studies assessed the impact of omega-3 on various clinical outcomes, such as mortality, hospitalization, cardiac function, and quality of life. Studied duration varied from weeks to years. Omega-3 supplementation demonstrated potential benefits such as improved heart function, reduced inflammation, and decreased risk of cardiovascular events. Conclusion: Omega-3 supplementation could benefit heart disease treatment, potentially reducing therapy duration and improving outcomes. Starting omega-3 supplementation for HF patients seems favorable.

show abstract

Polyunsaturated fatty acids supplementation impairs anti‐oxidant high‐density lipoprotein function in heart failure

Cited by 10 publications

References 19 publications

Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial

Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial

PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling

Omega-3 supplementation and outcomes of heart failure: A systematic review of clinical trials

Contact Info

Product

Resources

About